Semax vs Cerebrolysin
Synthetic ACTH fragment nootropic vs multi-peptide neurotrophic brain extract — comparing two established neuroprotective agents with different regulatory histories.
Last updated: 2026-03-08
Quick Comparison Table
| Category | Semax | Cerebrolysin |
|---|---|---|
| Structure | Synthetic heptapeptide (ACTH 4-10 analogue + Pro-Gly-Pro) | Multi-peptide complex from porcine brain |
| Primary Mechanism | BDNF/NGF upregulation, melanocortin pathway | Multi-neurotrophic factor mimetic |
| Administration | Intranasal drops | IV or IM injection |
| Approval Status | Approved in Russia/CIS (since 1994) | Approved in 40+ countries |
| Primary Indications | Stroke, cognitive enhancement, optic nerve atrophy | Stroke, TBI, Alzheimer's, vascular dementia |
| Convenience | Self-administered nasal drops | Requires IV/IM injection (clinical setting) |
| Evidence Base | Moderate — Russian clinical trials + Western preclinical | Extensive — 50+ international clinical trials |
| Side Effects | Very few — nasal irritation rare | Injection site reactions, headache, dizziness |
Mechanism of Action
Semax
Semax Mechanism:
Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic analogue of ACTH(4-10) with a C-terminal Pro-Gly-Pro extension that enhances stability and CNS penetration.
Key actions: 1. **BDNF upregulation** — Increases Brain-Derived Neurotrophic Factor expression by 2-4 fold 2. **NGF upregulation** — Stimulates Nerve Growth Factor production 3. **TrkB receptor activation** — Downstream BDNF signalling for neuroplasticity 4. **Dopaminergic modulation** — Enhances dopamine and serotonin turnover 5. **Anti-inflammatory** — Reduces neuroinflammation via IL-6 and TNF-α suppression
Semax does not bind melanocortin receptors despite its ACTH-derived structure — its nootropic effects are independent of the HPA axis.
Cerebrolysin
Cerebrolysin Mechanism:
A standardised multi-peptide preparation mimicking the activity of endogenous neurotrophic factors (BDNF, NGF, CNTF, GDNF).
Key actions: 1. **Multi-neurotrophic mimetic** — Acts on BDNF, NGF, CNTF, and GDNF pathways 2. **Neuroprotection** — Reduces excitotoxicity and calpain activation 3. **Neuroplasticity** — Promotes dendritic branching and LTP 4. **Anti-apoptotic** — Bcl-2 upregulation, caspase inhibition 5. **Neurogenesis** — Stimulates neural stem cell proliferation
Clinical Trial Evidence
Semax Clinical Studies
Participants: 120
Duration: 10 days
Semax (12mg/day intranasal) improved NIHSS scores and 30-day outcomes vs standard care in acute ischaemic stroke.
Statistically significant
Participants: 40
Duration: 10 days
Semax improved attention, memory, and cognitive processing speed in healthy volunteers compared to placebo.
Statistically significant
Participants: 30
Duration: 7 days
Semax increased serum BDNF levels by 2-4 fold. Effect correlated with cognitive improvement on psychometric testing.
Statistically significant
Participants: 60
Duration: 30 days
Intranasal Semax improved visual acuity and visual field in patients with optic nerve atrophy. Neuroprotective effect confirmed.
Statistically significant
Participants: 90
Duration: 30 days
Semax improved cognitive function, reduced anxiety, and improved cerebral blood flow in chronic cerebrovascular disease.
Statistically significant
Cerebrolysin Clinical Studies
Participants: 1070
Duration: 90 days
Cerebrolysin improved functional outcomes in acute ischaemic stroke. Significant NIHSS and Barthel Index improvement.
Statistically significant
Participants: 280
Duration: 24 weeks
30ml/day IV improved ADAS-cog by 3.2 points vs placebo in moderate Alzheimer's disease.
Statistically significant
Participants: 142
Duration: 28 days
Improved GCS scores and 6-month outcomes in moderate-severe TBI.
Statistically significant
Participants: 242
Duration: 24 weeks
Improved cognitive function and clinical global impression in vascular dementia.
Statistically significant
Participants: 4500
Duration: Multiple
Meta-analysis of 6 RCTs confirmed Cerebrolysin improves neurological outcomes in acute stroke with good safety profile.
Statistically significant
Benefits Comparison
Semax Unique Benefits
- Intranasal administration (no injection)
- Strong BDNF upregulation
- Cognitive enhancement in healthy individuals
- Approved since 1994 (30+ year track record in Russia)
- Minimal side effects
Shared Benefits
- Neuroprotection in stroke
- BDNF pathway enhancement
- Neuroplasticity promotion
- Clinical approval in multiple countries
- Well-tolerated safety profiles
Cerebrolysin Unique Benefits
- Larger international clinical trial database
- Multi-neurotrophic pathway activation
- Approved in 40+ countries
- Proven in stroke, TBI, and multiple dementias
- Meta-analysis confirmed efficacy
Research & Evidence
Semax Research
Semax has been extensively studied in Russian clinical trials since the early 1990s and has been an approved medication since 1994. Western preclinical studies have confirmed its BDNF-upregulating and neuroprotective properties. However, it has not undergone FDA/EMA regulatory evaluation or large-scale Western clinical trials.
Cerebrolysin Research
Cerebrolysin has the larger international evidence base — 50+ clinical trials including the CASTA stroke trial (1,070 patients), E-ADI Alzheimer's trial, and multiple meta-analyses. It is approved in 40+ countries, though not in the US or UK.
Head-to-Head Analysis
Direct Comparison:
Both are used clinically for stroke recovery in their respective approved markets, but no head-to-head trial exists.
Administration Advantage: Semax's intranasal delivery is a major practical advantage — self-administered, painless, and convenient. Cerebrolysin requires IV/IM injection in clinical settings.
Mechanism Overlap: Both upregulate BDNF pathways, but through different mechanisms. Semax stimulates endogenous BDNF production; Cerebrolysin provides exogenous BDNF-like peptide fragments. Both promote neuroplasticity and neuroprotection.
Evidence Scale: Cerebrolysin has more international clinical trial data. Semax's evidence is primarily from Russian research institutions, though it has been approved and used clinically in Russia since 1994.
Protocol Comparison
Semax Protocol
Semax Approved Protocols (Russia):
Cognitive Enhancement: 200-600mcg intranasal, 2-3 times daily. Cycles of 10-30 days.
Acute Stroke: 6-12mg intranasal daily for 10 days.
Optic Nerve: 200mcg intranasal, 2-3 times daily for 30 days.
Routes: Intranasal drops only (0.1% or 1% solution).
Cerebrolysin Protocol
Cerebrolysin Clinical Protocols:
Stroke: 30ml IV daily for 10-21 days. Alzheimer's: 10-30ml IV daily for 20 days, repeat every 3-6 months. TBI: 30-50ml IV daily for 5-10 days.
Routes: IV infusion or IM injection.
Safety Profiles
Semax Safety
Semax Safety:
Exceptionally well-tolerated. 30+ years of clinical use in Russia. Rare side effects: mild nasal irritation. No systemic adverse effects reported. No hormonal effects despite ACTH-derived structure. No abuse potential or withdrawal. Safe in elderly and paediatric populations.
Cerebrolysin Safety
Cerebrolysin Safety:
Well-characterised over 30 years. Common: injection site reactions, headache, dizziness (mild). Rare: allergic reactions (animal-derived). Contraindicated in epilepsy. Theoretical prion risk (porcine brain-derived) — no cases reported.
The Verdict
Both are established neuroprotective agents with decades of clinical use — Semax since 1994 in Russia, Cerebrolysin in 40+ countries. Semax offers the practical advantage of intranasal self-administration and strong BDNF upregulation. Cerebrolysin offers broader neurotrophic coverage and a larger international clinical trial database. For accessibility and convenience, Semax is preferred. For severe neurological conditions (stroke, TBI, dementia) with clinical supervision, Cerebrolysin has more robust evidence. Both represent validated peptide approaches to neuroprotection.
Frequently Asked Questions
Conclusion
Semax and Cerebrolysin are two of the most established neuroprotective peptide therapies in clinical use globally. Semax's intranasal convenience, strong BDNF upregulation, and exceptional tolerability make it attractive for both clinical and cognitive enhancement applications. Cerebrolysin's broader neurotrophic coverage and larger international trial database make it the more validated choice for serious neurological conditions. Both demonstrate that peptide-based neuroprotection is a viable therapeutic strategy with decades of real-world evidence.
Medical Disclaimer
The information provided in this comparison is for educational and research purposes only. Neither Semax nor Cerebrolysin is approved for human therapeutic use by the MHRA, EMA, or FDA. This content does not constitute medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement.